Eisai Company, Limited

Hiroyuki Kato

Takeshi Nagasu

Takashi Owa

Yoshiharu Mizui

Suguru Suzuki

Naoko Nagaoka

Shinji Yoshitake

Takatoshi Kawai

Toshio Seto

Akira Yokoi

Noboru Suzuki

Junro Kuromitsu

Susceptibility of a tumor cell to an anticancer agent is tested by measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in a tumor cell collected from a cancer patient treated with an anticancer agent (E7070 and related compounds thereof), or causing the anticancer agent to act on a tumor cell collected from a cancer patient and measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in the tumor cell, and determining that the tumor cell is susceptible to the anticancer agent when the expression level or levels of the gene or genes listed in Table 3 increase, or the expression level or levels of the gene or genes listed in Table 4 decrease.

Method of testing anticancer agent-sensitivity of tumor cells

A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the heparin binding site of human AT III into another amino acids with the use of the recombinant DNA technology with the use of a DNA coding for AT III as a template. The invention also relates to a method for mass producing the above-described mutant by incubating a host transformed by an expression vector having the cDNA of the mutant inserted therein.

Human antithrombin III mutants

Growing community of inventors

Ibaraki, Japan

Hiroyuki Kato